Insmed Inc (NASDAQ: INSM) was nothing short of a powerhouse last month, soaring 45%, while the S&P 500 index rose 3% in the same timeframe. What’s driving this surge? Insmed revealed that its Phase ...
InsmedINSM stock crumbled Thursday after the biotech company scrapped one of its brensocatib studies in what one analyst called a "worst-case scenario for the program." The company said brensocatib ...
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in ...
Insmed (NASDAQ:INSM) underwent analysis by 13 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of their recent ...
Hsbc Holdings PLC boosted its holdings in Insmed, Inc. (NASDAQ:INSM – Free Report) by 1.5% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The ...
BRIDGEWATER, N.J., Oct. 15, 2025 /PRNewswire/ -- Insmed Incorporated (INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the ...
In the latest quarter, 16 analysts provided ratings for Insmed (NASDAQ:INSM), showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ...
Insmed (NASDAQ:INSM) will release its quarterly earnings report on Thursday, 2026-02-19. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Insmed to report an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results